Massalia Therapeutics launches to advance novel treatments for complex conditions

Biotech spin-off targets fibrosis, neoplasm and neovascularization

Massalia Therapeutics, a biotechnology spin-off from the C2VN Institute, has officially launched with a mission to develop innovative treatments for patients with fibrotic, neoplastic and neovascularized conditions.

The company’s sole-in-class therapeutic platform bridges the intersection of these diseases, offering a new approach to tackling their complex interactions.

Co-founded by Landmark BioVentures and researchers from Aix-Marseille University, Massalia Therapeutics builds on 20 years of research led by Dr Marcel Blot-Chabaud and Pr Nathalie Bardin’s team at C2VN.

Their work led to the identification and validation of the SANF (Soluble Angiogenic Neoplastic and Fibrotic) factor, a novel target with transformational potential as a therapeutic platform.

“The depth of biological and translational validation behind SANF is remarkable,” said Zaki Sellam, executive chairman at Massalia, and CEO and co-founder of Landmark BioVentures. “Given its wide-ranging potential in oncology and fibrosis, we are confident that this therapeutic platform can redefine treatment paradigms in these challenging diseases.”

Massalia Therapeutics operates from C2VN at the Faculty of Pharmacy of Aix-Marseille University, a partner of La Timone University Hospital in Marseille. The company is backed by academic and strategic partners, including Aix-Marseille University, Marseille University Hospitals and SATT Sud-Est, a regional economic development agency.

“The launch of Massalia Therapeutics represents a significant milestone in the translation of academic innovation into clinical solutions,” said Françoise Dignat-George, director at C2VN.

Massalia Therapeutics is advancing towards clinical candidate nomination, with plans to begin IND-enabling studies within the next 6–12 months.